guaifenesin has been researched along with HIV Coinfection in 17 studies
Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.
| Excerpt | Relevance | Reference |
|---|---|---|
| "PHI-443 (N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea) is a rationally designed novel thiophene thiourea nonnucleoside reverse transcriptase inhibitor (NNRTI) with potent anti-HIV activity against the wild-type and drug-resistant primary clinical human immunodeficiency virus (HIV-1) isolates." | 3.72 | PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide. ( D'Cruz, OJ; Samuel, P; Uckun, FM, 2004) |
| "Guaifenesin therapy was associated with improved SNOT-16 scores, although there was not a detectable improvement in MCT." | 2.71 | Alterations of nasal mucociliary clearance in association with HIV infection and the effect of guaifenesin therapy. ( Calhoun, KH; Rosen, EJ, 2005) |
| "Women with bacterial vaginosis (BV) have a higher risk of HIV transmission but the cause of risk is unknown." | 1.35 | Effect of mucosal fluid from women with bacterial vaginosis on HIV trans-infection mediated by dendritic cells. ( Landay, AL; Martinson, JA; Simoes, JA; Spear, GT; St John, EP; Zariffard, MR, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Rosen, EJ | 1 |
| Calhoun, KH | 1 |
| Wawrose, SF | 1 |
| Tami, TA | 1 |
| Amoils, CP | 1 |
| Schaefer, A | 1 |
| Yang, B | 1 |
| Schroeder, HA | 1 |
| Harit, D | 2 |
| Humphry, MS | 1 |
| Ravel, J | 1 |
| Lai, SK | 4 |
| Hoang, T | 1 |
| Toler, E | 1 |
| DeLong, K | 1 |
| Mafunda, NA | 1 |
| Bloom, SM | 1 |
| Zierden, HC | 1 |
| Moench, TR | 1 |
| Coleman, JS | 1 |
| Hanes, J | 2 |
| Kwon, DS | 1 |
| Cone, RA | 1 |
| Ensign, LM | 1 |
| Gundavarapu, S | 1 |
| Mishra, NC | 1 |
| Singh, SP | 1 |
| Langley, RJ | 1 |
| Saeed, AI | 1 |
| Feghali-Bostwick, CA | 1 |
| McIntosh, JM | 1 |
| Hutt, J | 1 |
| Hegde, R | 1 |
| Buch, S | 1 |
| Sopori, ML | 1 |
| Stax, MJ | 1 |
| Mouser, EE | 1 |
| van Montfort, T | 1 |
| Sanders, RW | 1 |
| de Vries, HJ | 1 |
| Dekker, HL | 1 |
| Herrera, C | 1 |
| Speijer, D | 1 |
| Pollakis, G | 1 |
| Paxton, WA | 1 |
| Chen, A | 1 |
| McKinley, SA | 1 |
| Shi, F | 1 |
| Wang, S | 1 |
| Mucha, PJ | 1 |
| Forest, MG | 1 |
| Gunn, B | 1 |
| Schneider, J | 1 |
| Shansab, M | 1 |
| Bastian, AR | 1 |
| Fahrbach, K | 1 |
| Smith, A | 1 |
| Mahan, A | 1 |
| Karim, M | 1 |
| Licht, A | 1 |
| Zvonar, I | 1 |
| Tedesco, J | 1 |
| Anderson, M | 1 |
| Chapel, A | 1 |
| Suscovich, T | 1 |
| Malaspina, D | 1 |
| Streeck, H | 1 |
| Walker, BD | 1 |
| Kim, A | 1 |
| Lauer, G | 1 |
| Altfeld, M | 1 |
| Pillai, S | 1 |
| Szleifer, I | 1 |
| Kelleher, NL | 1 |
| Kiser, PF | 1 |
| Hope, TJ | 2 |
| Alter, G | 1 |
| St John, EP | 1 |
| Zariffard, MR | 1 |
| Martinson, JA | 1 |
| Simoes, JA | 1 |
| Landay, AL | 1 |
| Spear, GT | 1 |
| Hida, K | 1 |
| Shukair, S | 1 |
| Wang, YY | 1 |
| Figueiredo, A | 1 |
| Cone, R | 1 |
| Graham, SM | 1 |
| Masese, L | 1 |
| Gitau, R | 1 |
| Richardson, BA | 1 |
| Mandaliya, K | 1 |
| Peshu, N | 1 |
| Jaoko, W | 1 |
| Ndinya-Achola, J | 1 |
| Overbaugh, J | 1 |
| McClelland, RS | 1 |
| D'Cruz, OJ | 1 |
| Samuel, P | 1 |
| Uckun, FM | 1 |
| Verkuyl, DA | 1 |
| Mascolini, M | 1 |
| Ellerbrock, TV | 1 |
| Lennox, JL | 1 |
| Clancy, KA | 1 |
| Schinazi, RF | 1 |
| Wright, TC | 1 |
| Pratt-Palmore, M | 1 |
| Evans-Strickfaden, T | 1 |
| Schnell, C | 1 |
| Pai, R | 1 |
| Conley, LJ | 1 |
| Parrish-Kohler, EE | 1 |
| Bush, TJ | 1 |
| Tatti, K | 1 |
| Hart, CE | 1 |
2 trials available for guaifenesin and HIV Coinfection
| Article | Year |
|---|---|
Alterations of nasal mucociliary clearance in association with HIV infection and the effect of guaifenesin therapy.
Topics: Adult; Double-Blind Method; Expectorants; Female; Guaifenesin; HIV Infections; Humans; Male; Middle | 2005 |
The role of guaifenesin in the treatment of sinonasal disease in patients infected with the human immunodeficiency virus (HIV).
Topics: Adult; CD4-Positive T-Lymphocytes; Chronic Disease; Double-Blind Method; Guaifenesin; HIV Infections | 1992 |
15 other studies available for guaifenesin and HIV Coinfection
| Article | Year |
|---|---|
Broadly neutralizing antibodies consistently trap HIV-1 in fresh cervicovaginal mucus from select individuals.
Topics: Broadly Neutralizing Antibodies; Cervix Uteri; Female; HIV Infections; HIV-1; Humans; Immunoglobulin | 2023 |
Editorial Note: HIV gp120 Induces Mucus Formation in Human Bronchial Epithelial Cells through CXCR4/α7-Nicotinic Acetylcholine Receptors.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Epithelial Cells; HIV Infections; Humans; Mucus; Receptors, | 2023 |
The cervicovaginal mucus barrier to HIV-1 is diminished in bacterial vaginosis.
Topics: Adult; Bacteria; Cervix Uteri; Coinfection; Female; HIV Infections; HIV-1; Humans; Microbiota; Middl | 2020 |
HIV gp120 induces mucus formation in human bronchial epithelial cells through CXCR4/α7-nicotinic acetylcholine receptors.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiretroviral Therapy, Highly Active; Bronchi; Ep | 2013 |
Colorectal mucus binds DC-SIGN and inhibits HIV-1 trans-infection of CD4+ T-lymphocytes.
Topics: CD4-Positive T-Lymphocytes; Cell Adhesion Molecules; Cell Line, Tumor; Colon; Dendritic Cells; env G | 2015 |
Modeling of Virion Collisions in Cervicovaginal Mucus Reveals Limits on Agglutination as the Protective Mechanism of Secretory Immunoglobulin A.
Topics: Agglutination; Cervix Uteri; Female; HIV; HIV Infections; Humans; Immunoglobulin A, Secretory; Model | 2015 |
Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16.
Topics: Antibody Affinity; CA-125 Antigen; Female; Glycosylation; HIV Antibodies; HIV Infections; HIV-1; Hum | 2016 |
Effect of mucosal fluid from women with bacterial vaginosis on HIV trans-infection mediated by dendritic cells.
Topics: Adjuvants, Immunologic; Cell Adhesion Molecules; Dendritic Cells; Female; HIV Infections; HIV-1; Hum | 2009 |
Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus.
Topics: Animals; Cell Line; Cervix Uteri; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Hyd | 2009 |
Genital ulceration does not increase HIV-1 shedding in cervical or vaginal secretions of women taking antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Cervix Uteri; Female; HIV Infections; HIV-1; Humans; Mucus; Prospective Stud | 2011 |
PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide.
Topics: Absorption; Animals; Anti-Infective Agents; Biomechanical Phenomena; Cervix Uteri; Drug Stability; E | 2004 |
Mouth operated mucus extractors: safe to use?
Topics: HIV Infections; Humans; Infant; Infant Care; Infant, Newborn; Infectious Disease Transmission, Patie | 1995 |
The drugs we've got...the drugs we're getting...beyond blood. A three-part look at the Fourth Conference on Retroviruses and Opportunistic Infections.
Topics: Anti-HIV Agents; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infe | 1997 |
Viral load and progression.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV | 1997 |
Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions.
Topics: Adolescent; Adult; Cohort Studies; Drug Resistance, Microbial; Female; HIV Infections; HIV-1; Humans | 2001 |